시장보고서

상품코드

1297760

세계의 경구용 항당뇨병제 시장(2023-2030년)

Global Oral Anti-Diabetic Drugs Market - 2023-2030

발행일: 2023년 06월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 195 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

샘플 요청 목록에 추가

시장 개요

경구용 항당뇨병제 세계 시장은 2022년 443억 달러에 달할 것으로 예상되며, 2030년에는 최대 808억 달러에 달할 것으로 예상됩니다. 세계 경구용 항당뇨병제 시장은 예측 기간(2023-2030년) 동안 8.0%의 CAGR을 보일 것으로 예상됩니다.

2형 당뇨병 치료에 사용되는 특정 경구용 항당뇨병제는 환자별 특성, 병력, 치료 목적 등 여러 변수에 따라 환자마다 다릅니다. 예를 들어, 카나글리플로진, 다파글리플로진, 엠파글리플로진과 같은 SGLT2 억제제는 신장의 포도당 재흡수를 억제하여 소변 포도당 배설량을 증가시키고 혈당을 낮추는 작용을 합니다.

시장 역학

연구 활동의 활성화는 예측 기간 동안 세계 경구용 항당뇨병제 시장의 성장을 촉진하고 있습니다

예를 들어, 2022년 12월 화이자는 G 단백질 결합 수용체(GPCR)에 초점을 맞춘 구조 기반 약물 설계(SBDD) 및 개발의 세계 리더인 소성그룹(Societe Generale)에 화이자의 후보물질 PF-07081532가 임상 2상 시험에서 첫 번째 피험자에게 투여 투여되었음을 알렸습니다. 이 목표에 도달하면 소성헵타레스는 1,000만 달러를 지급받게 됩니다.

차세대 경구용 저분자 GLP-1 수용체 작용제 PF-07081532는 1일 1회 투여하는 제2형 당뇨병 및 비만 치료제로 개발되고 있습니다. 화이자의 과학자들은 소생헵탈의 독자적인 StaR(안정화 수용체) 기술을 활용한 다중 표적 연구 협력을 통해 PF-07081532를 발견했습니다. 화이자가 실시한 PF-07081532의 임상 1상 시험은 성공적이었습니다.

인식 개선과 정부의 노력이 예측 기간 동안 세계 경구용 항당뇨병제 시장의 성장을 촉진하고 있습니다

세계 최대 규모의 당뇨병 인식 개선 캠페인인 '세계 당뇨병의 날'은 160여 개국에서 10억 명 이상의 사람들이 참여합니다. 이 날을 기념하는 주요 목적은 당뇨병에 대한 인식을 높이고 사람들이 이 세계 건강의 큰 문제를 해결하기 위해 행동을 취하도록 촉구하는 것입니다. 2021-23년 세계 당뇨병의 날은 '당뇨병 치료 접근성'에 초점을 맞출 것입니다. "내일을 지키는 교육"은 2021-23 세계 당뇨병의 날 캠페인의 두 번째 해의 초점입니다.

2022년 캠페인은 의료진과 당뇨병 환자들에게 양질의 당뇨병 교육에 대한 접근성을 향상시켜야 한다는 점을 강조합니다. 이 활동은 의료진과 당뇨병 환자들이 양질의 당뇨병 교육을 받을 수 있도록 개선하는 것이 중요하다는 점을 강조합니다.

개별화 약물, 경구용 항당뇨병제 시장의 성장 기회 제공

데이터 과학과 기술의 급속한 발전은 치료와 예방 중재의 정확성을 향상시켜 적절한 환자에게 적절한 시기에 적절한 치료를 추천할 수 있게 해줄 수 있습니다. 제2형 당뇨병은 복잡하고 이질적인 다유전자성 대사 질환이기 때문에 "one size fits all" 전략은 효과적이지 않습니다.

유전학, 유전체학, 유전체학, 단백체학, 대사체학의 기술 발전으로 수천 개의 유전자, 단백질, 대사 산물을 효율적으로 분석할 수 있게 되었습니다. 이는 당뇨병과 같은 다양한 아형의 질병과 관련된 유전적 요인과 유전자 산물을 식별할 수 있는 새로운 기회를 제공하고 있습니다.

COVID-19 영향 분석

COVID-19는 경구용 항당뇨병제 시장에 큰 영향을 미치고 있으며, COVID-19로 인해 의료기관 방문이 감소하고 원격 의료 서비스에 대한 의존도가 높아지는 등 환자들의 행동이 변화하고 있습니다. 일부 당뇨병 환자들은 경구용 항당뇨병제를 구하기 어려워지거나 치료 계획을 지키기가 어려워져 이러한 약물에 대한 수요에 영향을 미쳤을 수 있습니다.

2023년 현재, COVID-19 상황이 회복되고 모든 의료시설이 환자들에게 접근이 용이하고 적절한 치료를 할 수 있게 됨에 따라 전 세계적으로 경구용 항당뇨병제 수요가 증가하고 있습니다.

러시아-우크라이나 분쟁 분석

러시아-우크라이나 분쟁이 경구용 항당뇨병제 시장에 미치는 영향은 복잡하고 다면적입니다. 분쟁으로 인해 사람들이 집을 떠나 다른 곳으로 피난을 가거나 안전을 위해 다른 곳으로 이동하게 되어 인구 이동이 발생할 수 있습니다. 피난민들은 의료 서비스, 특히 경구용 항당뇨병제에 대한 접근이 어려워져 당뇨병 관리가 중단될 수 있습니다. 러시아와 우크라이나는 모두 분쟁으로 인한 경제적 악영향을 받고 있습니다. 개인과 의료 시스템 모두 경구용 항당뇨병약의 가격 책정 및 가용성은 경제 불안정, 통화 변동 및 인플레이션 압력의 영향을 받고 있습니다.

비구아니드
- 메트포르민
α-글루코시다아제 억제제
도파민-D2 수용체 작용제
- 브로모크립틴(사이클로셋)
- 나트륨-글루코오스 공수송담체-2(SGLT-2) 억제제
- 인보카나(카나글리플로진)
- 자디앙스(엠파글리플로진)
- 팍시가/포시가(다파글리플로진)
- 수글랏(이프라글리플로진)
디펩티딜 펩티다아제-4(DPP-4) 억제제
- 자누비아(시타글립틴)
- 온글리자(삭사글립틴)
- 트라젠타(리나글립틴)
- 비피디아/네시나(알로글립틴)
- 갈부스(빌다글립틴)
설포닐우레아
메글리티나이드

제10장 제형별

액제
캡슐제
정제

제11장 유통 채널별

병원 약국
소매 약국
온라인 약국

제12장 지역별

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
남미
- 브라질
- 아르헨티나
- 기타 남미
아시아태평양
- 중국
- 인도
- 일본
- 호주
- 기타 아시아태평양
중동 및 아프리카

제13장 경쟁 상황

경쟁 시나리오
제품 벤치마크
기업 점유율 분석
주요 발전과 전략

제14장 기업 개요

Glenmark Pharma
- 기업 개요
- 제품 포트폴리오와 설명
- 재무 개요
- 주요 발전
Abbott
Biocon
Sanofi
Sunpharma
Novartis
Novo Nordisk
Merck
GlaxoSmithKline
Bristol-Myers Squibb

제15장 부록

ksm 23.07.11

Market Overview

The global Oral Anti-Diabetic Drugs Market reached US$ 44.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 80.8 billion by 2030. The global oral anti-diabetic drugs market is expected to exhibit a CAGR of 8.0% during the forecast period (2023-2030).

Based on a number of variables, such as the patient's unique characteristics, medical history, and treatment objectives, the specific oral anti-diabetic medications used in the treatment of type 2 diabetes vary in patients. For instance, SGLT2 inhibitors like canagliflozin, dapagliflozin, and empagliflozin function by preventing the kidneys' reabsorption of glucose, which causes an increase in urine glucose excretion and a decrease in blood sugar levels.

Market Dynamics

The Increasing Research Activities Are Boosting The Global Oral Anti-Diabetic Drugs Market Growth During The Forecast Period.

For instance, in December 2022, Pfizer notified Sosei Group Corporation, a global leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, that the candidate medicine PF-07081532 from Pfizer has been dosed to the first subject in Phase 2 clinical trial. When this goal is reached, Sosei Heptares will get a payment of $10 million USD.

Next-generation oral small molecule GLP-1 receptor agonist PF-07081532 is being developed as a once-daily treatment for Type 2 diabetes and obesity. In multi-target research cooperation where Pfizer has access to Sosei Heptare's unique StaR (stabilized receptor) technology, Pfizer scientists made the discovery of PF-07081532. The Pfizer-conducted Phase 1 clinical trial for PF-07081532 was successful.

The Growing Awareness And Government Initiatives Are Boosting The Global Oral Anti-Diabetic Drugs Market Growth During The Forecast Period.

The largest diabetes awareness campaign in the world, World Diabetes Day reaches over one billion individuals in more than 160 countries. The primary goal of honoring this day is to raise awareness of diabetes and encourage people to take action to address this major global health concern. Access to Diabetes Care is the focus of World Diabetes Day 2021-23. "Education to Protect Tomorrow" is the focus of the World Diabetes Day 2021-23 campaign's second year.

The emphasis of the campaign 2022 was on the requirement for improved accessibility to high-quality diabetes education for medical professionals and diabetic patients. Activities will emphasize the importance of improving health professionals' and diabetes patients' access to high-quality diabetes education.

Personalized Medicines Provide Oral Anti-Diabetic Drugs Market Growth Opportunities

Rapid developments in data science and technology have the potential to increase the accuracy of therapeutic and preventative interventions and make it possible to recommend the correct treatment to the right patient at the right time. A "one size fits all" strategy is ineffective for treating type 2 diabetes since it is a complex, heterogeneous, and polygenic palette of metabolic diseases.

The efficient analysis of thousands of genes, proteins, and metabolites is now possible due to technological advancements in genetics, genomics, proteomics, and metabolomics. This presents new opportunities for identifying genetic factors and gene products that are linked to various subtypes of diseases, such as diabetes mellitus.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the oral anti-diabetic drugs market. Patient behavior has changed as a result of COVID-19, including a decrease in visits to medical facilities and an increase in reliance on remote healthcare services. The demand for these medications may have been impacted because some diabetics may have had trouble getting access to oral anti-diabetes medications or sticking to their treatment plans.

As of 2023, the COVID-19 situation is recovering and all healthcare facilities are accessible for patients and can give proper treatment leading o increasing demand for oral anti-diabetic drugs worldwide.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the oral anti-diabetic drugs market is complex and multifaceted. Population displacement may occur as a result of the conflict because people may be compelled to evacuate their homes or seek safety elsewhere. Access to healthcare services, especially oral diabetes medications, is difficult for displaced people, which could interrupt the management of their diabetes. Both Russia and Ukraine have had negative economic impacts from the conflict. The pricing and availability of oral anti-diabetes medications for both individuals and healthcare systems are impacted by economic instability, currency fluctuations, and inflationary pressures.

Segment Analysis

The global oral anti-diabetic drugs market is segmented based on drug class, dosage type, distribution channel, and region.

The Dopamine -D2 Receptor Agonist Segment Is Expected To Hold A Position In The Market Over The Forecast Period.

The Dopamine -D2 receptor agonist segment accounted for 26.5% market share in the Oral Anti-Diabetic Drugs market in 2022. The research provides insights into the exact mechanism by which bromocriptine mesylate enhances glycemic control. However, it has been demonstrated that bromocriptine mesylate treatment in the morning improves glycemic control in T2D patients without raising plasma insulin concentrations.

This might be connected to the diurnal peak in central dopaminergic tone brought on by morning administration of the quick-release bromocriptine formulation in the brain regions that control peripheral fuel metabolism (including glucose, lipid metabolism, and protein metabolism).

Geographical Analysis

Increasing Collaborations And Partnerships Among The Key Players And Increasing Product Launches Dominate the Asia Pacific Region.

Asia Pacific is expected to dominate the oral anti-diabetic drugs market, accounting for around 24.4% of this market. For instance, in January 2022, earlier exclusively available as injections anti-diabetic medication has now been made available orally by Novo Nordisk India. The company reported that the new medication can help adults with type-2 diabetes better regulate their weight and blood sugar levels.

A naturally occurring hormone called glucagon-like peptide 1 is crucial in preserving the proper level of blood glucose. The only problem with peptide and protein-based biological treatments is that they must be administered intravenously, despite the fact that they are often quite successful.

Competitive Landscape

The major global players in the market include: Glenmark Pharma, Abbott, Biocon, Sanofi S.A., Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, and Bristol-Myers Squibb among others.

Why Purchase the Report?

To visualize the global oral anti-diabetic drugs market segmentation based on the drug class, dosage type, distribution channel, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of oral anti-diabetic drugs market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global oral anti-diabetic drugs market report would provide approximately 62 tables, 61 figures, and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Drug Class
3.2. Snippet by Dosage Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing prevalence of diabetes
- 4.1.2. Restraints
  - 4.1.2.1. Side effects associated with diabetic drugs
- 4.1.3. Opportunity
  - 4.1.3.1. Technological advancements
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Product

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.1.2. Market Attractiveness Index, By Product
- 9.1.3. Biguanides*
- 9.1.4. Introduction
- 9.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
  - 9.1.5.1. Metformin
- 9.1.6. Alpha-glucosidase inhibitors
- 9.1.7. Dopamine -D2 Receptor Agonist
  - 9.1.7.1. Bromocriptin (Cycloset)
  - 9.1.7.2. Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
  - 9.1.7.3. Invokana (Canagliflozin)
  - 9.1.7.4. Jardiance (Empagliflozin)
  - 9.1.7.5. Farxiga/Forxiga (Dapagliflozin)
  - 9.1.7.6. Suglat (Ipragliflozin)
- 9.1.8. Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
  - 9.1.8.1. Januvia (Sitagliptin)
  - 9.1.8.2. Onglyza (Saxagliptin)
  - 9.1.8.3. Tradjenta (Linagliptin)
  - 9.1.8.4. Vipidia/Nesina (Alogliptin)
  - 9.1.8.5. Galvus (Vildagliptin)
- 9.1.9. Sulfonylureas
- 9.1.10. Meglitinides

10. By Dosage Type

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
- 10.1.2. Market Attractiveness Index, By Dosage Type
10.2. Liquid*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Capsule
10.4. Tablet

11. By Distribution Channel

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel

11.2. Hospital Pharmacies*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.6.1. The U.S.
  - 12.2.6.2. Canada
  - 12.2.6.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.6.1. Germany
  - 12.3.6.2. The U.K.
  - 12.3.6.3. France
  - 12.3.6.4. Italy
  - 12.3.6.5. Spain
  - 12.3.6.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.6.1. Brazil
  - 12.4.6.2. Argentina
  - 12.4.6.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.6.1. China
  - 12.5.6.2. India
  - 12.5.6.3. Japan
  - 12.5.6.4. Australia
  - 12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies

14. Company Profiles

14.1. Glenmark Pharma*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. Abbott
14.3. Biocon
14.4. Sanofi
14.5. Sunpharma
14.6. Novartis
14.7. Novo Nordisk
14.8. Merck
14.9. GlaxoSmithKline
14.10. Bristol-Myers Squibb

LIST NOT EXHAUSTIVE

15. Appendix

15.1. About Us and Services
15.2. Contact Us